Cargando…

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

Patients with coronary artery disease remain at increased risk of recurrent life-threatening cardiovascular events even after adequate guideline-based treatment of conventional risk factors, including blood lipid levels. Inflammation is a critical pathway in the pathogenesis of atherosclerosis and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prescott, Eva, Pernow, John, Saraste, Antti, Åkerblom, Axel, Angerås, Oskar, Erlinge, David, Grove, Erik L., Hedman, Marja, Jensen, Lisette O., Svedlund, Sara, Kjaer, Magnus, Lagerström-Fermér, Maria, Gan, Li-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451793/ https://www.ncbi.nlm.nih.gov/pubmed/32875138 http://dx.doi.org/10.1016/j.conctc.2020.100629

Ejemplares similares

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
por: Ericsson, Hans, et al.
Publicado: (2018)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial
por: Anttila, Vesa, et al.
Publicado: (2020)

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD
por: Heerspink, Hiddo J.L., et al.
Publicado: (2021)

PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve
por: Haraldsson, Inger, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Adenoviral intramyocardial VEGF-D(ΔNΔC) gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up
por: Hartikainen, Juha, et al.
Publicado: (2017)

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2022)

A 13-lipoxygenase, TomloxC, is essential for synthesis of C5 flavour volatiles in tomato
por: Shen, Jiyuan, et al.
Publicado: (2014)

Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study
por: Patel, Ravi B., et al.
Publicado: (2021)

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2023)

PCI or CABG for left main coronary artery disease: the SWEDEHEART registry
por: Persson, Jonas, et al.
Publicado: (2023)

Lipoxygenases—Killers against Their Will?
por: Friedmann Angeli, José Pedro, et al.
Publicado: (2018)

Avenanthramides as lipoxygenase inhibitors
por: Landberg, Rikard, et al.
Publicado: (2020)

Clinical Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention in Patients Treated With Potent P2Y12 inhibitors ‐ a VALIDATE‐SWEDEHEART Substudy
por: Bergman, Sofia, et al.
Publicado: (2021)

Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids
por: Gheorghe, Karina Roxana, et al.
Publicado: (2009)

Lipoxygenase Inhibition by Plant Extracts
por: Lončarić, Melita, et al.
Publicado: (2021)

Collagen type III alpha I is a gastro-oesophageal reflux disease susceptibility gene and a male risk factor for hiatus hernia
por: Åsling, B, et al.
Publicado: (2009)

5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes
Publicado: (1993)

Effect of Arginase Inhibition on Ischemia-Reperfusion Injury in Patients with Coronary Artery Disease with and without Diabetes Mellitus
por: Kövamees, Oskar, et al.
Publicado: (2014)

Discovery of α-Linolenic Acid 16(S)-Lipoxygenase: Cucumber (Cucumis sativus L.) Vegetative Lipoxygenase 3
por: Gorina, Svetlana S., et al.
Publicado: (2023)

Recombinant Soybean Lipoxygenase 2 (GmLOX2) Acts Primarily as a ω6(S)-Lipoxygenase
por: Smirnova, Elena O., et al.
Publicado: (2023)

Inhibition of tumour growth by lipoxygenase inhibitors.
por: Hussey, H. J., et al.
Publicado: (1996)

Hydrogen Tunneling in a Prokaryotic Lipoxygenase
por: Carr, Cody A. Marcus, et al.
Publicado: (2014)

The Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease
por: Czapski, Grzegorz A., et al.
Publicado: (2015)

Regulation of Tissue Inflammation by 12-Lipoxygenases
por: Kulkarni, Abhishek, et al.
Publicado: (2021)

4-Aminobutyrate Aminotransferase (ABAT): Genetic and Pharmacological Evidence for an Involvement in Gastro Esophageal Reflux Disease
por: Jirholt, Johan, et al.
Publicado: (2011)

Arachidonic acid promotes the binding of 5-lipoxygenase on nanodiscs containing 5-lipoxygenase activating protein in the absence of calcium-ions
por: Kumar, Ramakrishnan B., et al.
Publicado: (2020)

Involvement of 15-lipoxygenase in early stages of atherogenesis
Publicado: (1994)

5-Lipoxygenase-mediated Endogenous DNA Damage
por: Jian, Wenying, et al.
Publicado: (2009)

Paired Hierarchical Organization of 13-Lipoxygenases in Arabidopsis
por: Chauvin, Adeline, et al.
Publicado: (2016)

Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis
por: Shah, Ron, et al.
Publicado: (2018)

Regulation and Functions of 15-Lipoxygenases in Human Macrophages
por: Snodgrass, Ryan G., et al.
Publicado: (2019)

Influence of Lipoxygenase Inhibition on Glioblastoma Cell Biology
por: Souza, Felipe da Costa, et al.
Publicado: (2020)

Biochemical Characterization of 13-Lipoxygenases of Arabidopsis thaliana
por: Maynard, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kmn8r4t9dass7ev1pm5eidgph2